Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089477 | 0.85 | EPHX2 (0.69) | EPHX2HPGD | |
| SCHEMBL3937303 | 0.81 | EPHX2 (0.77) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL3943499 | 0.75 | EPHX2 (0.80) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL27769249 | 0.75 | EPHX2 (0.66) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL3936624 | 0.74 | EPHX2 (1.00) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL10594359 | 0.73 | GAA (0.73) | SMN1; SMN2MAPTHPGDNPC1LMNA | |
| SCHEMBL4083187 | 0.73 | SMN1; SMN2 (0.58) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL5649930 | 0.73 | TSHR (0.67) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL4084025 | 0.72 | HPGD (0.60) | EPHX2SMN1; SMN2MAPTHPGDNPC1 | |
| SCHEMBL3945175 | 0.71 | EPHX2 (1.00) | EPHX2SMN1; SMN2MAPTHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | claimed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035949-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082350-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885SMN1; SMN2 4619/4885MAPT 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.